In contrast, TP53 mutations—a well‐known tumor suppressor gene—were associated with markedly worse OS compared to TP53 wild‐type patients (p < 0.001, log‐rank test), consistent with its role in driving aggressive disease progression. This evidence concerns the gene TP53 and neoplasm.